ArticleFrontiers in pediatrics2025
Lipidomics changes in bronchoalveolar lavage fluid of refractory mycoplasma pneumoniae pneumonia: LC-MS-based analysis of potential biomarkers and pathogenesis.
Article in Frontiers in pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Previous studies have reported the application of metabolomics in infectious diseases, but little is known about the potential function of bronchoalveolar lavage fluid (BALF) metabolites in children with (mycoplasma pneumoniae pneumonia) MPP and (refractory mycoplasma pneumoniae pneumonia) RMPP. Methods: In this study, untargeted lipidomic analysis of BALF in MPP patients ( Results: Thirteen differential lipids were found between RMPP and MPP, among which there were three significantly up-regulated differential metabolites (DG(34:4e), PC(36:5), SM(d38:3)), and the areas under the curves (AUCs) of all of them were greater than 0.8, and among the up-regulated differential metabolites of lipids between RMPP and MPP, DG(34:4e) and SM(d38:3) were positively correlated with Hydroxybutyrate Dehydrogenase (HBDH), Lactate Dehydrogenase (LDH), Creatine Kinase (CK), D-Dimer, and Fibrin Degradation Products (FDP). Conclusion: This is the first study to analyze the lipidomic features of BALF to differentiate between RMPP and MPP. The lipidomics of BALF in patients with RMPP was significantly altered and closely correlated with clinically relevant indicators. These data may contribute to the understanding of the pathogenesis of RMPP and the discovery of new biomarkers and therapeutic targets for RMPP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.